NYSE · SYK
Stryker Corporation
$311.36+$7.36 (+2.42%)
Stryker Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.03% below the high.
Loading market information…
NYSE · SNN · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Smith & Nephew plc’s quoted price sits in the lower half of its reported 52-week range, 18.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Smith & Nephew plc’s forward annual dividend is $0.62 per share, paid semi-annual. The forward yield is 2.05% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Smith & Nephew plc’s next earnings report is currently expected on Feb 23, 2027, with estimated earnings per share of $1.21. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Smith & Nephew plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2024 | Aug 1, 2024 | $0.75-4.33% vs estimate | $2.83B+0.07% vs estimate |
|---|
| Q2 2023 | Aug 3, 2023 | $0.70-4.64% vs estimate | $2.73B+0.5% vs estimate |
|---|
| Q4 2022 | Feb 21, 2023 | $0.87+19.18% vs estimate | $2.62B+0.54% vs estimate |
|---|
THE ANALYST VIEW
23 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $31.85.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$311.36+$7.36 (+2.42%)
Stryker Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.03% below the high.
$97.47+$1.08 (+1.12%)
Zimmer Biomet Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.01% below the high.
$82.91+$1.65 (+2.03%)
Globus Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.23% below the high.
$11.37-$0.08 (-0.7%)
Alphatec Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.18% below the high.
$45.72-$0.04 (-0.09%)
CONMED Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.8% below the high.
$22.81+$0.90 (+4.11%)
Enovis Corporation’s quoted price sits in the lower half of its reported 52-week range, 29.62% below the high.
$12.83+$0.59 (+4.82%)
Integra LifeSciences Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 37.38% below the high.
$31.52+$0.72 (+2.34%)
OrthoPediatrics Corp.’s quoted price sits in the upper half of its reported 52-week range, 3.37% below the high.
